Source:http://www.reactome.org/biopax/48887BiochemicalReaction4077
| Predicate | Object |
|---|---|
| rdf:type | |
| biopax3:comment |
Authored: Jassal, B, 2011-10-19,
Edited: Jassal, B, 2011-10-19,
Heparan-alpha-glucosaminide N-acetyltransferase (HGSNAT) acetylates the non-reducing terminal alpha-glucosamine residue of heparin or heparan sulfate. This is a critical reaction for the degradation of heparan sulfate because there is no enzyme that can act on the unacetylated glucosamine molecule. The mechanism by which HGSNAT uses cytosolic acetyl-CoA to transfer the acetyl group to the lysosomal luminal substrate is unknown (Fan et al. 2006). A catalytically inactive 77-kDa precursor is transported to the lysosome and is cleaved into a 29kDa N-terminal alpha-chain and a 48kDa C-terminal beta-chain, which are assembled into active 440kDa oligomers in the lysosomal membrane (Durand et al. 2010). Defects in HGSNAT cause mucopolysaccharidosis type 3C (MPS3C) (MIM:252930), also called Sanfilippo C syndrome (Fan et al. 2006, Hrebicek et al. 2006).,
Reviewed: D'Eustachio, P, 2012-03-28
|
| biopax3:xref | |
| biopax3:dataSource | |
| biopax3:displayName |
HGSNAT acetylates the terminal N-glucosamine in heparan sulfate
|
| biopax3:eCNumber |
2.3.1.78
|
| biopax3:left | |
| biopax3:right |